Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Characterization of the genetic variation present in CYP3A4 in three South African populations.

Drögemöller B, Plummer M, Korkie L, Agenbag G, Dunaiski A, Niehaus D, Koen L, Gebhardt S, Schneider N, Olckers A, Wright G, Warnich L.

Front Genet. 2013 Feb 18;4:17. doi: 10.3389/fgene.2013.00017.

2.

Analysis of pharmacogenetic traits in two distinct South African populations.

Ikediobi O, Aouizerat B, Xiao Y, Gandhi M, Gebhardt S, Warnich L.

Hum Genomics. 2011 May;5(4):265-82.

3.

Genetic contribution to variable human CYP3A-mediated metabolism.

Lamba JK, Lin YS, Schuetz EG, Thummel KE.

Adv Drug Deliv Rev. 2002 Nov 18;54(10):1271-94. Review.

PMID:
12406645
4.

Genetic variation in eleven phase I drug metabolism genes in an ethnically diverse population.

Solus JF, Arietta BJ, Harris JR, Sexton DP, Steward JQ, McMunn C, Ihrie P, Mehall JM, Edwards TL, Dawson EP.

Pharmacogenomics. 2004 Oct;5(7):895-931.

PMID:
15469410
5.

Characterization of the genetic profile of CYP2C19 in two South African populations.

Drögemöller BI, Wright GE, Niehaus DJ, Koen L, Malan S, Da Silva DM, Hillermann-Rebello R, La Grange AM, Venter M, Warnich L.

Pharmacogenomics. 2010 Aug;11(8):1095-103. doi: 10.2217/pgs.10.90.

PMID:
20712527
6.

A pharmacogenetic study of CD4 recovery in response to HIV antiretroviral therapy in two South African population groups.

Parathyras J, Gebhardt S, Hillermann-Rebello R, Grobbelaar N, Venter M, Warnich L.

J Hum Genet. 2009 May;54(5):261-5. doi: 10.1038/jhg.2009.20.

PMID:
19282874
7.

Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.

Dandara C, Lombard Z, Du Plooy I, McLellan T, Norris SA, Ramsay M.

Pharmacogenomics. 2011 Dec;12(12):1663-70. doi: 10.2217/pgs.11.106.

8.

Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.

Lee JS, Cheong HS, Kim LH, Kim JO, Seo DW, Kim YH, Chung MW, Han SY, Shin HD.

Korean J Physiol Pharmacol. 2013 Dec;17(6):479-84. doi: 10.4196/kjpp.2013.17.6.479.

9.

Characterization of CYP1A2, CYP2C19, CYP3A4 and CYP3A5 polymorphisms in South Brazilians.

Kohlrausch FB, Carracedo Á, Hutz MH.

Mol Biol Rep. 2014 Mar;41(3):1453-60. doi: 10.1007/s11033-013-2990-8.

PMID:
24443221
10.

Common allelic variants of cytochrome P4503A4 and their prevalence in different populations.

Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, Strom S, Zhang J, Schuetz EG.

Pharmacogenetics. 2002 Mar;12(2):121-32.

PMID:
11875366
11.

Sequence variation and linkage disequilibrium in the GABA transporter-1 gene (SLC6A1) in five populations: implications for pharmacogenetic research.

Hirunsatit R, Ilomäki R, Malison R, Räsänen P, Ilomäki E, Kranzler HR, Kosten T, Sughondhabirom A, Thavichachart N, Tangwongchai S, Listman J, Mutirangura A, Gelernter J, Lappalainen J.

BMC Genet. 2007 Oct 17;8:71.

12.

Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population.

Wright GE, Niehaus DJ, Drögemöller BI, Koen L, Gaedigk A, Warnich L.

Ann Hum Genet. 2010 Jul;74(4):340-50. doi: 10.1111/j.1469-1809.2010.00585.x.

13.

Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects.

Matimba A, Del-Favero J, Van Broeckhoven C, Masimirembwa C.

Hum Genomics. 2009 Jan;3(2):169-90.

14.

Systematic screening for polymorphisms in the CYP3A4 gene in the Chinese population.

Du J, Xing Q, Xu L, Xu M, Shu A, Shi Y, Yu L, Zhang A, Wang L, Wang H, Li X, Feng G, He L.

Pharmacogenomics. 2006 Sep;7(6):831-41.

PMID:
16981844
15.

Genetic variability of CYP3A4 in a heterogeneous Brazilian population from Maranhão.

Monteiro SC, de Sousa IH, Belfort IK, Nunes JD, Penha BA, dos Santos M, Drumond Louro I, da Silva ID.

Genet Mol Res. 2016 Feb 19;15(1). doi: 10.4238/gmr.15017275.

16.

Human loci involved in drug biotransformation: worldwide genetic variation, population structure, and pharmacogenetic implications.

Maisano Delser P, Fuselli S.

Hum Genet. 2013 May;132(5):563-77. doi: 10.1007/s00439-013-1268-5.

PMID:
23354977
17.

Genetic signature consistent with selection against the CYP3A4*1B allele in non-African populations.

Schirmer M, Toliat MR, Haberl M, Suk A, Kamdem LK, Klein K, Brockmöller J, Nürnberg P, Zanger UM, Wojnowski L.

Pharmacogenet Genomics. 2006 Jan;16(1):59-71.

PMID:
16344723
18.

Pharmacogenetics in American Indian populations: analysis of CYP2D6, CYP3A4, CYP3A5, and CYP2C9 in the Confederated Salish and Kootenai Tribes.

Fohner A, Muzquiz LI, Austin MA, Gaedigk A, Gordon A, Thornton T, Rieder MJ, Pershouse MA, Putnam EA, Howlett K, Beatty P, Thummel KE, Woodahl EL.

Pharmacogenet Genomics. 2013 Aug;23(8):403-14. doi: 10.1097/FPC.0b013e3283629ce9.

19.

Contrasting exome constancy and regulatory region variation in the gene encoding CYP3A4: an examination of the extent and potential implications.

Creemer OJ, Ansari-Pour N, Ekong R, Tarekegn A, Plaster C, Bains RK, Itan Y, Bekele E, Bradman N.

Pharmacogenet Genomics. 2016 Jun;26(6):255-70. doi: 10.1097/FPC.0000000000000207.

PMID:
27139836
20.

Mutation analysis of the human CYP3A4 gene 5' regulatory region: population screening using non-radioactive SSCP.

Hamzeiy H, Vahdati-Mashhadian N, Edwards HJ, Goldfarb PS.

Mutat Res. 2002 Mar 20;500(1-2):103-10.

PMID:
11890939

Supplemental Content

Support Center